Morningstar15d
Alentis Announces Positive Topline Results from Two Studies of Lixudebart (ALE.F02) in Patients with ANCA-RPGN and Advanced Liver Fibrosis
Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1 ... Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV ...
Yahoo Finance15d
Alentis Announces Positive Topline Results from Two Studies of Lixudebart (ALE.F02) in Patients with ANCA-RPGN and Advanced Liver Fibrosis
BASEL, Switzerland, January 09, 2025--(BUSINESS WIRE)--Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for Claudin-1 ...